Latanoprostene bunod
Glaucoma · Rx
Trade namesVyzulta
Drug classProstaglandin analog + nitric oxide donor
Strength0.024%
AvailabilityRx
Mechanism of actionMetabolized to latanoprost acid (uveoscleral outflow) plus butanediol mononitrate, which releases nitric oxide to relax the trabecular meshwork and increase conventional outflow, dual mechanism.
Indication / reason for useOpen-angle glaucoma and ocular hypertension.
Usual adult dosing1 drop once daily in the evening.
PreservativeBAK 0.02%
Contact lensesRemove lenses; reinsert after 15 minutes.
Common / important adverse effectsConjunctival hyperemia, eye irritation, pain on instillation, lash and pigment changes.
Contraindications & cautionsAs for the PGA class.
Pregnancy / lactationAvoid where possible.
Practice notesModestly greater IOP lowering than latanoprost in head-to-head studies.
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.